Systematic Identification of Oncogenic EGFR Interaction Partners

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Epidermal growth factor receptor (EGFR) is a receptor tyrosine kinase (TK) implicated in various cancers due to overexpression or mutation.
• Aberrant EGFR signaling drives tumor growth, necessitating the identification of novel interaction partners for drug discovery.
• Understanding mutated EGFR signaling pathways is crucial for developing targeted cancer therapies.

Purpose of the Study:

• To systematically identify novel proteins interacting with EGFR in cancer signaling.
• To investigate the role of identified interaction partners, particularly with oncogenic EGFR variants.
• To explore the therapeutic potential of targeting identified EGFR interaction partners in non-small cell lung cancer (NSCLC).

Main Methods:

• Utilized high-content imaging and a mammalian membrane two-hybrid protein-protein interaction assay.
• Identified and validated novel EGFR interaction partners.
• Employed small hairpin RNA (shRNA) for TACC3 depletion and small-molecule inhibitors for targeting TACC3.

Main Results:

• Eight novel EGFR interaction partners were identified.
• Half of the identified partners showed strong interaction with hyperactive EGFR variants.
• Transforming acidic coiled-coil proteins (TACC) 3 was found to stabilize cell surface EGFR, enhancing downstream signaling via MAPK and AKT pathways.
• TACC3 depletion or inhibition reduced mitogenic signaling in NSCLC cell lines.

Conclusions:

• TACC3 plays a critical role in stabilizing EGFR and promoting oncogenic signaling in NSCLC.
• Targeting TACC3 presents a promising therapeutic strategy for NSCLC treatment.
• The identified novel EGFR interactors offer potential new targets for cancer drug discovery.